Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neuroimmunomodulation

• Publication date

  2015-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000441004PMID 26599431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defining the clinical course of multiple sclerosis: The 2013 revisions

  2015cited by this paper
• A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.

  2015cited by this paper
• Multiple sclerosis: Lessons from molecular neuropathology

  2014cited by this paper
• Transcriptomic Profile Reveals Gender-Specific Molecular Mechanisms Driving Multiple Sclerosis Progression

  2014cited by this paper
• High prevalence of increased interleukin-17A serum levels in postmenopausal estrogen deficiency

  2014cited by this paper
• Defining the clinical course of multiple sclerosis

  2014cited by this paper
• IL‐17 and Glutamate Excitotoxicity in the Pathogenesis of Multiple Sclerosis

  2014cited by this paper
• IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments.

  2014cited by this paper
• Incidence and prevalence of multiple sclerosis in Europe: a systematic review

  2013cited by this paper
• Longitudinal interferon-β effects in multiple sclerosis: differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13.

  2013cited by this paper
• Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis

  2013cited by this paper
• Current and Future Therapies for Multiple Sclerosis

  2013cited by this paper
• Sex-hormone receptors pattern on regulatory T-cells: clinical implications for multiple sclerosis

  2012cited by this paper
• Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies

  2012cited by this paper
• Regulation of CD4+ T‐cell polarization by suppressor of cytokine signalling proteins

  2012cited by this paper
• Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids.

  2011cited by this paper
• Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?

  2011cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• Th1 and Th17 cells

  2010cited by this paper
• Gender and sex hormones in multiple sclerosis pathology and therapy.

  2009cited by this paper
• Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?

  2009cited by this paper
• Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?

  2008cited by this paper
• Prognostic factors in multiple sclerosis.

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

  2007cited by this paper
• The influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a review

  2005cited by this paper
• The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.

  2005cited by this paper
• Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

  2005cited by this paper
• Immunology of multiple sclerosis.

  2005cited by this paper
• Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

  2005cited by this paper
• The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• The multiple sclerosis severity score

  2003cited by this paper
• Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.

  2003cited by this paper
• Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

  2002cited by this paper
• Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

  2002cited by this paper
• Natural history of multiple sclerosis: implications for counselling and therapy

  2002cited by this paper
• Multiple sclerosis.

  2002cited by this paper
• Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis.

  2000cited by this paper
• Multiple sclerosis.

  2000cited by this paper
• Interferon‐γ Modulates Human Oligodendrocyte Susceptibility To Fas‐Mediated Apoptosis

  2000cited by this paper
• Multiple Sclerosis: Levels of Interleukin‐10‐Secreting Blood Mononuclear Cells are Low in Untreated Patients but Augmented During Interferon‐β‐1b Treatment

  1999cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Interferon-γ-Induced Oligodendrocyte Cell Death: Implications for the Pathogenesis of Multiple Sclerosis

  1995cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• [Immunology of multiple sclerosis].

  1982cited by this paper

• The function of long non-coding RNA IFNG-AS1 in autoimmune diseases

  2024cites this paper
• Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA—A Preliminary Study

  2023cites this paper
• Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients

  2022cites this paper
• Role of interleukin-17 signaling pathway in the interaction between multiple sclerosis and acute myocardial infarction.

  2022cites this paper
• Pleiotrophin serum level is increased in Relapsing-Remitting Multiple Sclerosis and correlates with sex, BMI and treatment.

  2021cites this paper
• Vitamin D status, proinflammatory cytokines and bone mineral density in Mexican people with multiple sclerosis.

  2021cites this paper
• Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.

  2020cites this paper
• Impact of EBV on Multiple in a Sample of Iraqi Females: Immunological and Molecular Study

  2020cites this paper
• Impact of EBV on multiple sclerosis in some of the Iraqi males: Immunological and molecular study

  2020cites this paper
• Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability

  2019cites this paper
• Implications of immunotherapy with high-dose glatiramer acetate in acute phase of spinal cord injury in rats

  2019cites this paper
• Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls

  2018cites this paper
• Multiple Sclerosis in Search for Biomarkers: Gender as a Variable in the Equation

  2018cites this paper
• Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis.

  2018cites this paper
• Multiple Sclerosis and Obesity: Possible Roles of Adipokines

  2016cites this paper